Novacyt S.A. (EPA:ALNOV)

Market Cap	26.16M -23.1%
Revenue (ttm)	22.69M +39.5%
Net Income	-35.47M
EPS	-0.51
Shares Out	72.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	84,071
Average Volume	94,076
Open	0.3650
Previous Close	0.3665
Day's Range	0.3555 - 0.3650
52-Week Range	0.3555 - 0.7350
Beta	0.97
RSI	35.46
Earnings Date	Apr 30, 2026

About Novacyt

Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 234
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNOV

Financial Performance

In 2024, Novacyt's revenue was 19.63 million, an increase of 84.82% compared to the previous year's 10.62 million. Losses were -41.76 million, 47.6% more than in 2023.

Financial numbers in GBP